BIOMARKER:

FLT3-TKD mutation

Entrez ID:

Related biomarkers:

‹

›

FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	gilteritinib Sensitive: A2 - Guideline EHA 2022 - 2 weeks (NewA2)	gilteritinib Sensitive: A2 - Guideline EHA 2022 - 2 weeks - (New B)
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	midostaurin Sensitive: A2 - Guideline	midostaurin Sensitive: A2 - Guideline
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	venetoclax + azacitidine Sensitive: B - Late Trials	venetoclax + azacitidine Sensitive: B - Late Trials
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	LY3009120 Sensitive: C3 – Early Trials	LY3009120 Sensitive: C3 – Early Trials
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Sensitive: C3 – Early Trials	venetoclax + gilteritinib Sensitive: C3 – Early Trials
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	sorafenib + gilteritinib Sensitive: C3 – Early Trials	sorafenib + gilteritinib Sensitive: C3 – Early Trials
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	JRF104 Sensitive: D – Preclinical	JRF104 Sensitive: D – Preclinical
FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	FLT3-TKD mutation FLT3-TKD mutation	Acute Myelogenous Leukemia AML	PHI-101 Sensitive: D – Preclinical	PHI-101 Sensitive: D – Preclinical